B. Riley Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
B. Riley Securities analyst Kalpit Patel maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $29.
B. Riley Securities analyst Kalpit Patel maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $29.